Xbiotech Stock Price Prediction
| XBIT Stock | USD 7.61 0.26 3.54% |
Oversold Vs Overbought
41
Oversold | Overbought |
Wall Street Target Price 18 | Quarterly Revenue Growth (0.93) |
Using XBiotech hype-based prediction, you can estimate the value of XBiotech from the perspective of XBiotech response to recently generated media hype and the effects of current headlines on its competitors.
The fear of missing out, i.e., FOMO, can cause potential investors in XBiotech to buy its stock at a price that has no basis in reality. In that case, they are not buying XBiotech because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.
XBiotech after-hype prediction price | USD 7.13 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
XBiotech |
XBiotech After-Hype Price Prediction Density Analysis
As far as predicting the price of XBiotech at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in XBiotech or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of XBiotech, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
XBiotech Estimiated After-Hype Price Volatility
In the context of predicting XBiotech's stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on XBiotech's historical news coverage. XBiotech's after-hype downside and upside margins for the prediction period are 2.60 and 11.66, respectively. We have considered XBiotech's daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
XBiotech is slightly risky at this time. Analysis and calculation of next after-hype price of XBiotech is based on 3 months time horizon.
XBiotech Stock Price Prediction Analysis
Have you ever been surprised when a price of a Company such as XBiotech is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading XBiotech backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with XBiotech, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.54 | 4.53 | 0.48 | 0.08 | 4 Events / Month | 2 Events / Month | In about 4 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | ||
7.61 | 7.13 | 6.31 |
|
XBiotech Hype Timeline
XBiotech is at this time traded for 7.61. The entity has historical hype elasticity of -0.48, and average elasticity to hype of competition of 0.08. XBiotech is forecasted to decline in value after the next headline, with the price expected to drop to 7.13. The average volatility of media hype impact on the company price is over 100%. The price decrease on the next news is expected to be -6.31%, whereas the daily expected return is at this time at 0.54%. The volatility of related hype on XBiotech is about 3178.95%, with the expected price after the next announcement by competition of 7.69. About 35.0% of the company outstanding shares are owned by insiders. The company has Price to Book (P/B) ratio of 1.21. Historically many companies with similar price-to-book (P/B) ratio do better than the market in the long run. XBiotech recorded a loss per share of 1.08. The entity last dividend was issued on the 15th of July 2021. Given the investment horizon of 90 days the next forecasted press release will be in about 4 days. Check out XBiotech Basic Forecasting Models to cross-verify your projections.XBiotech Related Hype Analysis
Having access to credible news sources related to XBiotech's direct competition is more important than ever and may enhance your ability to predict XBiotech's future price movements. Getting to know how XBiotech's peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how XBiotech may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| TFFP | Tff Pharmaceuticals | (0.13) | 4 per month | 0.00 | (0.13) | 11.28 | (12.99) | 95.77 | |
| ELYM | Eliem Therapeutics | 0.25 | 4 per month | 0.00 | (0.19) | 6.21 | (9.35) | 34.87 | |
| INBX | Inhibrx | 1.00 | 6 per month | 2.72 | 0.01 | 5.54 | (6.11) | 16.80 | |
| ELVN | Enliven Therapeutics | (0.55) | 9 per month | 2.18 | 0.01 | 5.84 | (4.07) | 12.96 |
XBiotech Additional Predictive Modules
Most predictive techniques to examine XBiotech price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for XBiotech using various technical indicators. When you analyze XBiotech charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
About XBiotech Predictive Indicators
The successful prediction of XBiotech stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as XBiotech, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of XBiotech based on analysis of XBiotech hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to XBiotech's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to XBiotech's related companies. | 2023 | 2024 (projected) | Dividend Yield | 0.2 | 0.18 | Price To Sales Ratio | 23.98 | 14.88 |
Story Coverage note for XBiotech
The number of cover stories for XBiotech depends on current market conditions and XBiotech's risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that XBiotech is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about XBiotech's long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.
Contributor Headline
Latest Perspective From Macroaxis
XBiotech Short Properties
XBiotech's future price predictability will typically decrease when XBiotech's long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of XBiotech often depends not only on the future outlook of the potential XBiotech's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. XBiotech's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 30.4 M | |
| Cash And Short Term Investments | 200 M |
Additional Tools for XBiotech Stock Analysis
When running XBiotech's price analysis, check to measure XBiotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy XBiotech is operating at the current time. Most of XBiotech's value examination focuses on studying past and present price action to predict the probability of XBiotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move XBiotech's price. Additionally, you may evaluate how the addition of XBiotech to your portfolios can decrease your overall portfolio volatility.